{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:55:58Z","timestamp":1784231758387,"version":"3.55.0"},"reference-count":39,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Crafoordska Foundation","award":["2017-00696"],"award-info":[{"award-number":["2017-00696"]}]},{"name":"Crafoordska Foundation","award":["100470Pj"],"award-info":[{"award-number":["100470Pj"]}]},{"name":"Berta Kamprad Foundation","award":["2017-00696"],"award-info":[{"award-number":["2017-00696"]}]},{"name":"Berta Kamprad Foundation","award":["100470Pj"],"award-info":[{"award-number":["100470Pj"]}]},{"name":"Alfred \u00d6sterlunds Foundation","award":["2017-00696"],"award-info":[{"award-number":["2017-00696"]}]},{"name":"Alfred \u00d6sterlunds Foundation","award":["100470Pj"],"award-info":[{"award-number":["100470Pj"]}]},{"name":"Greta and Johan Kock Foundation","award":["2017-00696"],"award-info":[{"award-number":["2017-00696"]}]},{"name":"Greta and Johan Kock Foundation","award":["100470Pj"],"award-info":[{"award-number":["100470Pj"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish research Council","doi-asserted-by":"publisher","award":["2017-00696"],"award-info":[{"award-number":["2017-00696"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish research Council","doi-asserted-by":"publisher","award":["100470Pj"],"award-info":[{"award-number":["100470Pj"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["2017-00696"],"award-info":[{"award-number":["2017-00696"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["100470Pj"],"award-info":[{"award-number":["100470Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guard Therapeutics International","award":["2017-00696"],"award-info":[{"award-number":["2017-00696"]}]},{"name":"Guard Therapeutics International","award":["100470Pj"],"award-info":[{"award-number":["100470Pj"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is used clinically to treat metastasized or unresectable neuroendocrine tumors (NETs). Although 177Lu-DOTATATE is mostly well tolerated in patients, bone marrow suppression and long-term renal toxicity are still side effects that should be considered. Amino acids are often used to minimize renal radiotoxicity, however, they are associated with nausea and vomiting in patients. \u03b11-microglobulin (A1M) is an antioxidant with heme- and radical-scavenging abilities. A recombinant form (rA1M) has previously been shown to be renoprotective in preclinical models, including in PRRT-induced kidney damage. Here, we further investigated rA1M\u2019s renal protective effect in a mouse 177Lu-DOTATATE model in terms of administration route and dosing regimen and as a combined therapy with amino acids (Vamin). Moreover, we investigated the protective effect of rA1M on peripheral blood and bone marrow cells, as well as circulatory biomarkers. Intravenous (i.v.) administration of rA1M reduced albuminuria levels and circulatory levels of the oxidative stress-related protein fibroblast growth factor-21 (FGF-21). Dual injections of rA1M (i.e., at 0 and 24 h post-177Lu-DOTATATE administration) preserved bone marrow cellularity and peripheral blood reticulocytes. Administration of Vamin, alone or in combination with rA1M, did not show any protection of bone marrow cellularity or peripheral reticulocytes. In conclusion, this study suggests that rA1M, administered i.v. for two consecutive days in conjunction with 177Lu-DOTATATE, may reduce hematopoietic and kidney toxicity during PRRT with 177Lu-DOTATATE.<\/jats:p>","DOI":"10.3390\/biom13060928","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T02:41:35Z","timestamp":1685673695000},"page":"928","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recombinant \u03b11-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a 177Lu-DOTATATE Mouse Radiation Model"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-4416","authenticated-orcid":false,"given":"Abdul Ghani","family":"Alattar","sequence":"first","affiliation":[{"name":"Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, 221 84 Lund, Sweden"},{"name":"Division of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, 221 84 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2898-7129","authenticated-orcid":false,"given":"Amanda","family":"Kristiansson","sequence":"additional","affiliation":[{"name":"Pediatrics, Department of Clinical Sciences Lund, Sk\u00e5ne University Hospital, Lund University, 221 84 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Pediatrics, Department of Clinical Sciences Lund, Sk\u00e5ne University Hospital, Lund University, 221 84 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Vallius","sequence":"additional","affiliation":[{"name":"Pediatrics, Department of Clinical Sciences Lund, Sk\u00e5ne University Hospital, Lund University, 221 84 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Ahlstedt","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, CIPA, Lund University, 221 84 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-4368","authenticated-orcid":false,"given":"Eva","family":"Forssell-Aronsson","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Sciences, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"\u00c5kerstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Section for Infection Medicine, Lund University, 221 84 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5343-0213","authenticated-orcid":false,"given":"Sven-Erik","family":"Strand","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Oncology, Lund University, 222 42 Lund, Sweden"},{"name":"Department of Clinical Sciences Lund, Medical Radiation Physics, Lund University, 221 85 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1962-5276","authenticated-orcid":false,"given":"Johan","family":"Flygare","sequence":"additional","affiliation":[{"name":"Division of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, 221 84 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5880-2925","authenticated-orcid":false,"given":"Magnus","family":"Gram","sequence":"additional","affiliation":[{"name":"Pediatrics, Department of Clinical Sciences Lund, Sk\u00e5ne University Hospital, Lund University, 221 84 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","article-title":"Neuroendocrine tumors, version 1.2015","volume":"13","author":"Kulke","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"ref_3","first-page":"34","article-title":"Symptoms and quality of life in gastroenteropancreatic neuroendocrine tumours","volume":"3","author":"Srirajaskanthan","year":"2015","journal-title":"EMJ Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Camus, B., Cottereau, A.S., Palmieri, L.J., Dermine, S., Tenenbaum, F., Brezault, C., and Coriat, R. (2021). Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061267"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/ERC-19-0400","article-title":"PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)","volume":"27","author":"Sorbye","year":"2020","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1\u2013SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-015-3001-1","article-title":"Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment","volume":"42","author":"Svensson","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beem.2015.10.005","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"30","author":"Brabander","year":"2016","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: Prognostic factors, incidence and course","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: Incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MNM.0000000000001198","article-title":"Nephrotoxicity\/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: A systematic review","volume":"41","author":"Stolniceanu","year":"2020","journal-title":"Nucl. Med. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fphys.2021.645650","article-title":"Structure, Functions, and Physiological Roles of the Lipocalin \u03b11-Microglobulin (A1M)","volume":"12","author":"Bergwik","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1089\/ars.2018.7517","article-title":"Protection of Kidney Function with Human Antioxidation Protein alpha1-Microglobulin in a Mouse (177)Lu-DOTATATE Radiation Therapy Model","volume":"30","author":"Kristiansson","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.2967\/jnumed.118.225243","article-title":"Recombinant \u03b11-Microglobulin Is a Potential Kidney Protector in 177Lu-Octreotate Treatment of Neuroendocrine Tumors","volume":"60","author":"Andersson","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kristiansson, A., \u00d6rbom, A., Ahlstedt, J., Karlsson, H., Zedan, W., Gram, M., \u00c5kerstr\u00f6m, B., Strand, S.E., Altai, M., and Strand, J. (2021). (177)Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant \u03b1(1)-Microglobulin (A1M), Including Kidney Damage Assessment Using (99m)Tc-MAG3 Imaging. Biomolecules, 11.","DOI":"10.3390\/biom11020263"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/ars.2017.7181","article-title":"rA1M-035, a Physicochemically Improved Human Recombinant \u03b1(1)-Microglobulin, Has Therapeutic Effects in Rhabdomyolysis-Induced Acute Kidney Injury","volume":"30","author":"Rutardottir","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"N\u00e4\u00e4v, \u00c5., Erlandsson, L., Axelsson, J., Larsson, I., Johansson, M., Wester-Rosenl\u00f6f, L., M\u00f6rgelin, M., Cassl\u00e9n, V., Gram, M., and \u00c5kerstr\u00f6m, B. (2015). A1M Ameliorates Preeclampsia-Like Symptoms in Placenta and Kidney Induced by Cell-Free Fetal Hemoglobin in Rabbit. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125499"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wester-Rosenl\u00f6f, L., Cassl\u00e9n, V., Axelsson, J., Edstr\u00f6m-H\u00e4gerwall, A., Gram, M., Holmqvist, M., Johansson, M.E., Larsson, I., Ley, D., and Marsal, K. (2014). A1M\/\u03b11-Microglobulin Protects from Heme-Induced Placental and Renal Damage in a Pregnant Sheep Model of Preeclampsia. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086353"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kristiansson, A., Gram, M., Flygare, J., Hansson, S.R., \u00c5kerstr\u00f6m, B., and Storry, J.R. (2020). The Role of \u03b11-Microglobulin (A1M) in Erythropoiesis and Erythrocyte Homeostasis\u2014Therapeutic Opportunities in Hemolytic Conditions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197234"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.freeradbiomed.2020.02.018","article-title":"Human radical scavenger \u03b11-microglobulin protects against hemolysis in vitro and \u03b11-microglobulin knockout mice exhibit a macrocytic anemia phenotype","volume":"162","author":"Kristiansson","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2967\/jnumed.121.262069","article-title":"Dosimetric quantities in neuroendocrine tumors over treatment cycles with 177Lu-DOTATATE","volume":"63","author":"Roth","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kristiansson, A., \u00d6rbom, A., Vilhelmsson Timmermand, O., Ahlstedt, J., Strand, S.-E., and \u00c5kerstr\u00f6m, B. (2021). Kidney Protection with the Radical Scavenger \u03b11-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy. Antioxidants, 10.","DOI":"10.3390\/antiox10081271"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.freeradbiomed.2014.06.025","article-title":"A1M, an extravascular tissue cleaning and housekeeping protein","volume":"74","author":"Akerstrom","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref_27","first-page":"333","article-title":"Biodistribution and pharmacokinetics of recombinant \u03b11-microglobulin and its potential use in radioprotection of kidneys","volume":"5","author":"Ahlstedt","year":"2015","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"L17","DOI":"10.1530\/ERC-15-0543","article-title":"High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy","volume":"23","author":"Brieau","year":"2016","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: The value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/RLU.0000000000004203","article-title":"Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men","volume":"47","author":"Minczeles","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1748-717X-8-35","article-title":"Regulation of protein translation initiation in response to ionizing radiation","volume":"8","author":"Trivigno","year":"2013","journal-title":"Radiat. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2021.10.005","article-title":"Targeting elevated heme levels to treat a mouse model for Diamond-Blackfan Anemia","volume":"105","author":"Chen","year":"2022","journal-title":"Exp. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1667\/RR2213.1","article-title":"Bystander Cell Death and Stress Response is Inhibited by the Radical Scavenger \u03b11-Microglobulin in Irradiated Cell Cultures","volume":"174","author":"Olsson","year":"2010","journal-title":"Radiat. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2016.12.024","article-title":"Fibroblast growth factor 21 and its novel association with oxidative stress","volume":"11","year":"2017","journal-title":"Redox Biol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lin, Z., Zhou, Z., Liu, Y., Gong, Q., Yan, X., Xiao, J., Wang, X., Lin, S., Feng, W., and Li, X. (2011). Circulating FGF21 Levels Are Progressively Increased from the Early to End Stages of Chronic Kidney Diseases and Are Associated with Renal Function in Chinese. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018398"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1089\/ars.2012.4658","article-title":"The radical-binding lipocalin A1M binds to a Complex I subunit and protects mitochondrial structure and function","volume":"18","author":"Olsson","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kristiansson, A., Davidsson, S., Johansson, M.E., Piel, S., Elm\u00e9r, E., Hansson, M.J., \u00c5kerstr\u00f6m, B., and Gram, M. (2020). \u03b11-Microglobulin (A1M) protects human proximal tubule epithelial cells from heme-induced damage in vitro. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165825"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Walrand, S., and Jamar, F. (2021). Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead. Int. J. Mol. Sci., 22.","DOI":"10.20944\/preprints202105.0445.v1"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ekir.2023.02.1071","article-title":"Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics","volume":"8","author":"Weiss","year":"2023","journal-title":"Kidney Int. Rep."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/6\/928\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:46:59Z","timestamp":1760125619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/6\/928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["biom13060928"],"URL":"https:\/\/doi.org\/10.3390\/biom13060928","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}